171 related articles for article (PubMed ID: 8219217)
21. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A
Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527
[TBL] [Abstract][Full Text] [Related]
25. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
[TBL] [Abstract][Full Text] [Related]
26. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
27. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ
Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
[TBL] [Abstract][Full Text] [Related]
29. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma.
Ghetie MA; Podar EM; Gordon BE; Pantazis P; Uhr JW; Vitetta ES
Int J Cancer; 1996 Sep; 68(1):93-6. PubMed ID: 8895546
[TBL] [Abstract][Full Text] [Related]
30. Large scale preparation of immunotoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain.
Ghetie V; Ghetie MA; Uhr JW; Vitetta ES
J Immunol Methods; 1988 Sep; 112(2):267-77. PubMed ID: 3262139
[TBL] [Abstract][Full Text] [Related]
31. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Liu XY; Pop LM; Schindler J; Vitetta ES
MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
[TBL] [Abstract][Full Text] [Related]
32. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1994 Aug; 84(3):702-7. PubMed ID: 7519071
[TBL] [Abstract][Full Text] [Related]
33. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
[TBL] [Abstract][Full Text] [Related]
34. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
Ghetie V; Swindell E; Uhr JW; Vitetta ES
J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
[TBL] [Abstract][Full Text] [Related]
36. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
van Horssen PJ; van Oosterhout YV; Evers S; Backus HH; van Oijen MG; Bongaerts R; de Witte T; Preijers FW
Leukemia; 1999 Feb; 13(2):241-9. PubMed ID: 10025898
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
38. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
39. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Engert A; Diehl V; Schnell R; Radszuhn A; Hatwig MT; Drillich S; Schön G; Bohlen H; Tesch H; Hansmann ML; Barth S; Schindler J; Ghetie V; Uhr J; Vitetta E
Blood; 1997 Jan; 89(2):403-10. PubMed ID: 9002941
[TBL] [Abstract][Full Text] [Related]
40. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Pop LM; Liu X; Ghetie V; Vitetta ES
Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
